SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (128)3/24/1998 12:21:00 AM
From: Larry Liebman  Respond to of 668
 
I called the company for their perspective. This is what I heard:
(a) The primary endpoint for the trials was to establish OP-1 as equivalent to autograft. The data supported that conclusion.
(b) The P.M.A. should be filed by Stryker in April, perhaps May.
(c) All the CBMI financial analysts were at the Florida meeting on Saturday for the disclosure of results. The analysts, having reviewed the data, maintained their buy/strong buy recommendations.

Good luck to all.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News